501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Improves
Performance of FAIMS Marijuana
Breathalyzer –
CNN
Coverage
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- January
7, 2020
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer
of marijuana breathalyzer devices for law enforcement and the
workplace, reports that engineers have
developed
and deployed new ion optics methods that have resulted in a 6 times
increase in analyte signal which has increased
the sensitivity
in the
Company's FAIMS (field
asymmetric waveform ion mobility spectrometry)
?9-tetrahydrocannabinol
("THC")
detection
device. The Company has
been working for the last several months on improving
"ion
optics" which is a critical component
of the FAIMS system in order to better focus and maximize
ion
flow
through
the FAIMS cell "keyhole". Members of Cannabix advisory team,
including Dr. Yost and Dr.
Purves were instrumental
in providing guidance on the latest technological
enhancements
leading to this improvement. Furthermore, the Company reports
that Cannabix scientists
have been testing with a
single stage, direct breath with the FAIMS device, that allows
for real-time
collection and analysis of low volatility
compounds without
sample preparation.
In
addition, Company engineers have been pushing forward
development of its
THC
Breath Analyzer ("THCBA") which incorporates microfluidic sensor
technology for the detection of ?9-tetrahydrocannabinol ("THC")
from breath. As announced in November, engineers have reduced the
size of several components inside the THCBA for a
more
compact
device, over the course of December, engineers have been
further
optimizing breath
sample chamber design and
tested additional sensors that work in conjunction
with microfluidic
sensor. Furthermore,
the form factor
(exterior) design of the THCBA will see additional refinements in
due course.
The
Company reports that it has received notable media coverage from
CNN in an article titled, "Testing drivers for cannabis is hard.
Here's why" published recently
in
CNN
Business. The article makes mention of Cannabix Technologies'
development work with
its
marijuana
breathalyzer technologies. The full article
can be viewed at:
https://www.cnn.com/2020/01/02/business/cannabis-breathalyzers-are-coming-to-market/index.html
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable tools to market to enhance detection of marijuana impaired
driving offences on roads at a time when marijuana is becoming
legal in many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular,
Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine
testing for THC metabolite that requires an invasive collection and
reflects usage,
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.